MTOR and neoplasm: PDX HBCx-118 (BRCA2 and AKT1 mutated) responded to the combination of AZD5363 plus fulvestrant, while PDX HBCx-142 (AKT1 and mTOR mutated) responded with tumour regression to everolimus and with stable disease to volasertib, AZD5363 and palbo + fulvestrant.